News

A new, highly transmissible COVID subvariant has been detected in California — heightening the risk of a summer wave as ...
The horrifically cruel realities of the dairy industry know no bounds, and both documented abuse and unseen acts of brutality behind closed doors occur daily. Furthermore, bird flu outbreaks have ...
Kennedy Jr. together with U.S. Food and Drug Administration (FDA) Commissioner Dr. Mary Makary announced a new round of food dye bans on Tuesday at a press conference. The agencies shared their ...
He covers federal public health agencies. Senior Food and Drug Administration leaders are planning for cutbacks to the number of routine food and drug inspections conducted by the agency ...
HHS Secretary Robert F. Kennedy Jr. and US Food and Drug Administration Commissioner Marty Makary will share more about the administration’s plans on Tuesday, the advisory said. In January ...
The agencies aim to remove the dyes by the end of next year. The Department of Health and Human Services and the Food and Drug Administration announced on Tuesday a series of measures to phase out ...
today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug ...
The US Food and Drug Administration announced a plan Tuesday to phase out eight petroleum-based synthetic food dyes from America’s food supply in the coming months. “Food dye is just a no-brainer.
Languages: English. The Food and Drug Administration (FDA) has announced plans to phase out several petroleum-based synthetic food dyes from the U.S. food supply, a decision that could reshape ...
WASHINGTON, April 17 (Reuters) - The Food and Drug Administration is suspending a quality control program for its food testing laboratories as a result of staff cuts at the Department of Health ...
One analyst said the odds of a long-awaited approval for its Covid-19 vaccine have gone up "quite a bit." What NIH cuts would mean for local biotech, health sectors ...
MOLBREEVI was well-tolerated in the IMPALA-2 trial, with 97% of patients completing the double-blind period of the trial and no discontinuations from adverse events that were considered drug-related.